01 Industry overview
The tms therapy industry at a glance
The global transcranial magnetic stimulation system market is estimated at $310.8 million in 2026, with demand expanding as accelerated protocols, broader indications and outpatient mental-health care increase adoption.
- $310.8M[6]
- Global market size, 2026
- 9.7%[6]
- Forecast CAGR, 2026–2033
- 57.2%[6]
- North America share, 2025
- 79.8%[6]
- Depression application share, 2025
- Market size
- The global transcranial magnetic stimulation system market was valued at $279.5 million in 2025 and is estimated at $310.8 million in 2026. The market definition covers TMS systems rather than the full value of clinical treatment services.[6]
- Forecast & CAGR
- Global market revenue is forecast to reach $594.5 million by 2033, representing a 9.7% compound annual growth rate from 2026 to 2033. Grand View Research identifies rising neurological and psychological disorder prevalence, technology development and product awareness as growth factors.[6]
- Market share & regions
- North America held 57.2% of global revenue in 2025, making it the leading region. Asia Pacific is identified as the fastest-growing regional market through 2033, while the report covers North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.[6]
- Segmentation
- The market is segmented by type, application, age group and region. rTMS accounted for 66.5% of revenue in 2025, depression represented 79.8% of application revenue, and adults represented 95.5% of age-group revenue.[6]
- Key players & concentration
- The industry is moderately fragmented rather than dominated by a single supplier. Major and emerging participants include NeuroStar (Neuronetics), BrainsWay, MagVenture, Magstim, Nexstim, Neurosoft, eNeura, Soterix Medical and several Chinese manufacturers; four manufacturers held 61.7% of the 81 FDA TMS-treatment-system authorizations recorded through September 21, 2026, a regulatory measure that does not equal sales share.[6][1]
- Pricing
- Published U.S. self-pay prices in 2026 had a median of $7,472 for a standard course and $228 for a session, based on 17 and 20 clinic price lists respectively. Original Medicare allowed an average of $180.94 for a 2024 office follow-up session and paid $143.48, with state averages ranging from $103.34 to $217.46.[1]
- Trends, drivers & challenges
- Accelerated TMS is shortening treatment schedules: MagVenture received U.S. clearance in May 2026 for protocols delivering at least two sessions per day for adult major depressive disorder. Key challenges include the need for repeated clinic visits, uneven reimbursement and incomplete evidence on optimal targeting, combinations and long-term outcomes.[7][8][1]
- Consumer behavior & competition
- A typical conventional rTMS course involves daily sessions five days per week for four to six weeks, which favors providers able to offer convenient outpatient access and accelerated alternatives. Competition centers on clinical evidence, regulatory clearances, neuronavigation, software and provider training; the FDA recorded 81 TMS treatment-system authorizations from 2008 through September 21, 2026, with 13 in 2025.[8][1][6]
- M&A
- The most significant recent transaction was Neuronetics’ acquisition of Greenbrook TMS, completed on December 9, 2024, combining NeuroStar technology with Greenbrook’s network of 95 U.S. treatment clinics. BrainsWay also acquired a minority stake in Axis Integrated Mental Health in June 2025, extending strategic investment into clinic operations.[9][10]
- Regulation
- In the United States, TMS treatment systems are generally regulated as Class II devices through 510(k) clearance or the De Novo pathway. Medicare coverage policies require an FDA-approved device, documented medical necessity and progress monitoring; the CMS policy permits up to 20 visits over four weeks, followed by tapering visits, with additional treatment subject to response criteria.[11][12]
- Latest news
- In 2026, MagVenture received FDA clearance for accelerated TMS protocols for adult major depressive disorder, while Wave Neurosciences’ MeRT system received FDA clearance for PTSD in July. FDA records also show a new rTMS system authorization dated September 6, 2026, indicating continued expansion of device competition and clinical indications.[7][13][14]
02 Ranking
Top 9 Companies in the Tms Therapy Industry
The leading companies in the tms therapy industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 20, 2026 · Next review December 20, 2026
BrainsWay stands out for Deep TMS systems because it commercializes Deep TMS systems for psychiatric disorders, while MagVenture focuses on non-invasive TMS treatment systems since it is a privately owned Danish manufacturer.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in TMS device
BrainsWay
IL
Ranked #1 · 9.1 · TMS device manufacturers
Why we picked it: It develops and commercializes Deep TMS systems for psychiatric disorders, supported by an 8.3% operating margin.
Leader in TMS clinic
neurocare group
DE
Ranked #4 · 8.7 · TMS clinic operators
Why we picked it: It operates and supports TMS clinics across the US, Europe and Australia, tied to a clinical TMS platform.
Leader in neuronavigation systems
Rogue Research
CA
Ranked #5 · 8.5 · Neuronavigation systems
Why we picked it: Its Brainsight navigation adoption in 1,500 laboratories positions it within neuronavigation and stimulation workflows.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | BrainsWay TMS device manufacturers · IL | 9.1 | 7.8 | 9.9 | 9.9 | 9.9 | |
Company snapshot · BrainsWay · Data as of November 20, 2026 Develops and commercializes Deep TMS systems for psychiatric disorders.[10]
| |||||||
| 2 | MagVenture TMS device manufacturers · DK | 8.8 | 9.9 | 9.0 | 7.7 | 8.2 | |
Company snapshot · MagVenture · Data as of November 20, 2026 Privately owned Danish manufacturer of non-invasive TMS treatment systems.[7]
| |||||||
| 3 | Nexstim TMS device manufacturers · FI | 8.8 | 7.3 | 9.8 | 9.6 | 9.9 | |
Company snapshot · Nexstim · Data as of November 20, 2026 Provides navigated TMS systems for therapy, diagnostics and neuroscience research.[15]
| |||||||
| 4 | neurocare group TMS clinic operators · DE | 8.7 | 8.8 | 9.4 | 9.1 | 7.0 | |
Company snapshot · neurocare group · Data as of November 20, 2026 Operates and supports TMS clinics across the US, Europe and Australia.[16]
| |||||||
| 5 | Rogue Research Neuronavigation systems · CA | 8.5 | 7.8 | 9.0 | 9.1 | 8.2 | |
Company snapshot · Rogue Research · Data as of November 20, 2026 Its Brainsight navigator is used in 1,500 laboratories for TMS and related applications.[17]
| |||||||
| 6 | Magnus Medical Accelerated SAINT TMS therapy systems, United States · US | 8.5 | 7.0 | 9.4 | 9.1 | 9.4 | |
Company snapshot · Magnus Medical · Data as of November 20, 2026 Develops the FDA-cleared SAINT accelerated neuromodulation system for depression.[18]
| |||||||
| 7 | Soterix Medical Clinical and research TMS and neuromodulation systems, US · US | 8.4 | 7.8 | 9.0 | 8.8 | 8.2 | |
Company snapshot · Soterix Medical · Data as of November 20, 2026 Markets SPRY TMS and MEGA-TMS systems for clinical and research use.[19]
| |||||||
| 8 | DEYMED Diagnostic TMS, EEG and EMG diagnostic systems, Czech Republic · CZ | 8.4 | 7.8 | 9.8 | 8.8 | 7.0 | |
Company snapshot · DEYMED Diagnostic · Data as of November 20, 2026 Develops and supplies TMS devices alongside EEG, EMG and polysomnography systems.[20]
| |||||||
| 9 | Magstim Clinical, research and navigated TMS systems, United Kingdom · GB | 8.1 | 9.9 | 7.0 | 7.0 | 7.0 | |
Company snapshot · Magstim · Data as of November 20, 2026 Supplies TMS, EEG and tDCS solutions for clinical and research use worldwide.[21]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 20, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 20). Top 9 companies in the tms therapy industry. In Tms Therapy Industry Statistics. Gitnux. https://gitnux.org/tms-therapy-industry-statistics/#top-companies
Share of verified U.S. TMS clinics naming each device brand on their website
NeuroStar leads with 69.1%.
03 Trends & forecasts
Top 10 Tms Therapy Industry Trends & Forecasts 2027
What is changing in the tms therapy industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Global market growth remains near 10%
High confidenceThe global TMS system market was valued at $279.5 million in 2025 and is estimated at $310.8 million in 2026. It is forecast to reach $594.5 million by 2033, implying a 9.7% CAGR from 2026 to 2033.[6]
Forecast 2027: In 2027, the market should remain on a high-single-digit growth path, supported by broader provider adoption, new indications and increased treatment utilization. Growth is likely to remain stronger for systems linked to differentiated clinical workflows than for undifferentiated hardware.
02North America retains regional leadership
High confidenceNorth America represented 57.2% of global TMS system revenue in 2025. The United States alone generated $136.5 million in TMS system revenue in 2025 and is forecast to reach $276.8 million by 2033.[6]
Forecast 2027: North America should remain the largest regional market in 2027, although its global share may edge down as Asia Pacific expands faster. U.S. demand will continue to be supported by established reimbursement pathways, specialist clinics and a large installed base.
03Asia Pacific expands faster than mature markets
Medium confidenceGrand View Research identifies Asia Pacific as the fastest-growing regional market through 2033, while North America held the largest share in 2025. The report attributes expansion to rising awareness, increasing neurological and mental-health needs and growing adoption in healthcare facilities.[6]
Forecast 2027: In 2027, suppliers should prioritize China, Japan, South Korea, Australia and other Asia-Pacific markets through local distribution, regulatory filings and hospital partnerships. Regional growth is likely to exceed the global average, but reimbursement and clinical-training constraints will limit the pace of conversion.
04Depression remains the core application
High confidenceDepression accounted for 79.8% of TMS system application revenue in 2025. Medicare coverage policies continue to describe outpatient TMS primarily around adults with severe major depressive disorder who have not benefited from initial treatment.[6][12]
Forecast 2027: Depression should remain the dominant application in 2027, likely accounting for most new clinic capacity and treatment volume. Growth will increasingly come from relapse treatment, maintenance protocols and patients seeking alternatives after unsuccessful medication trials.
05Accelerated protocols gain commercial traction
High confidenceThe FDA cleared MagVenture’s Accelerated TMS Therapy System on May 22, 2026. The clearance supports protocols delivering at least two sessions per day for adults with major depressive disorder, addressing the time burden of conventional daily treatment.[14]
Forecast 2027: In 2027, accelerated TMS will expand from specialist and self-pay settings into more mainstream outpatient offerings. Adoption will be strongest where clinics can improve equipment utilization and where payers accept treatment schedules that differ from conventional courses.
06Indications broaden beyond depression
High confidenceWave Neuroscience’s MeRT System received FDA 510(k) clearance for adults with PTSD on June 3, 2026. BrainsWay reported that its Deep TMS system had an installed base of approximately 1,781 systems at December 31, 2025 and was commercializing systems for multiple indications, including MDD, OCD and smoking addiction.[14][10]
Forecast 2027: The number of commercially promoted indications should increase in 2027, with PTSD, OCD, smoking addiction and neurological conditions receiving greater attention. Depression will still dominate revenue, but indication expansion should improve equipment utilization and reduce dependence on a single clinical market.
07Personalized targeting becomes a differentiator
Medium confidenceWave Neuroscience describes MeRT as an EEG-guided TMS system that measures brain activity before treatment and uses those data to personalize stimulation. Grand View Research also identifies technology development as a major market growth factor and highlights neuro-navigation activity among suppliers.[6]
Forecast 2027: In 2027, EEG guidance, neuronavigation and software-assisted targeting should become more prominent in product positioning. These features will command a premium mainly when manufacturers can connect personalization to measurable response improvements or operational efficiency.
08Recurring clinic-service models expand
High confidenceBrainsWay reported that, as of December 31, 2025, 699 of its 1,781 installed systems were leased rather than sold. Its commercial model also includes fixed-fee leases, add-on helmets, warranties and variable usage fees tied to treatments.[10]
Forecast 2027: Leasing, usage-based pricing and bundled service contracts should gain share in 2027 because they reduce providers’ upfront capital burden. Vendors with financing capacity and recurring-revenue infrastructure will be better positioned to place systems in smaller behavioral-health practices.
09Clinic networks strengthen purchasing power
High confidenceNeuronetics reported $149.2 million in 2025 revenue after incorporating Greenbrook TMS, including $87.0 million in clinic revenue and $14.3 million in U.S. NeuroStar system revenue. The company shipped 161 NeuroStar systems in the United States during 2025, while focusing on higher-volume accounts.[22]
Forecast 2027: In 2027, multi-site behavioral-health groups should account for a growing share of system purchases and treatment volume. Network operators will seek standardized protocols, centralized training, payer contracting and higher equipment utilization, increasing pressure on suppliers to offer enterprise terms.
10Supplier competition remains active
High confidenceFDA records show a May 2026 clearance for MagVenture’s accelerated system and a June 2026 clearance for Wave Neuroscience’s MeRT system. A 2026 review of FDA records identified 81 TMS treatment-system authorizations through September 21, 2026, with 13 authorizations in 2025 and nine through September 21, 2026.[14][1]
Forecast 2027: The U.S. device field should remain competitive in 2027, with new clearances and indication extensions sustaining product launches. Competition will increasingly center on clinical evidence, workflow software, targeting, training and service economics rather than coil hardware alone.
04 Statistics
Market Intelligence
This section anchors demand and coverage levels, including 10,477 Original Medicare patients and 231,177 Original Medicare TMS sessions in 2024.
Market size and service revenue in the tms therapy industry
- 10,477 Original Medicare patients received office-based TMS in the United States in 2024; the service category covers Medicare-billed office-based treatment.[1]
- $180.94 was the average Medicare-allowed amount per TMS treatment session in the United States in 2024; the category covers office-based TMS therapy.[1]
- 231,177 Original Medicare TMS sessions were billed by published clinicians in the United States in 2024; the category covers HCPCS 90868 treatment sessions.[1]
Firm counts and size structure in the tms therapy industry
- 190 U.S. mental health treatment facilities offered transcranial magnetic stimulation in 2024; this broader facility population is the closest official aggregate covering TMS therapy providers.[2]
- 196 multi-location groups held 51.5% of verified TMS clinic locations in the United States in September 2026; groups are defined by shared website domains.[1]
- 1,779 verified TMS clinic locations operated in the United States in September 2026; the directory counts locations whose websites confirmed TMS, not all national clinics.[1]
Regional breakdown of the tms therapy industry
- Utah had 12.8 verified TMS clinics per million residents in September 2026, the highest state rate; the denominator uses 2020 Census population.[1]
- Florida accounted for 31.2% of U.S. Original Medicare TMS sessions in 2024, with 107,365 sessions; the category covers Medicare-billed TMS treatment.[1]
- Mississippi had 0.7 verified TMS clinics per million residents in September 2026, the lowest state rate; the denominator uses 2020 Census population.[1]
05 Statistics
Operating Benchmarks
This section quantifies published Medicare billing and patient volume, including a median of 375 treatment sessions per clinician in 2024.
Operating metrics used in the tms therapy industry
- The median published U.S. Medicare TMS clinician billed 375 treatment sessions in 2024, with the middle half billing 258–552 sessions; sessions use HCPCS 90868.[1]
- The median published U.S. Medicare TMS clinician treated 16 patients in 2024, with the middle half treating 13–23 patients; publication requires at least 11 patients.[1]
- 190 U.S. mental health treatment facilities offered TMS in 2024; SAMHSA defines the measure as facilities reporting transcranial magnetic stimulation among treatment approaches offered.[2]
06 Statistics
Clients & Demand
This section ties clinic directory presence to payer mix, including that 39.6% of verified locations listed Medicare in September 2026.
Service penetration and outsourcing in the tms therapy industry
- 32.8 Original Medicare beneficiaries per 100,000 received TMS on an office-plus-facility basis in the United States in 2024; the denominator is Original Medicare beneficiaries.[1]
- 39.6% of verified U.S. TMS clinic locations listed Medicare in September 2026, equal to 705 locations; the denominator is 1,779 verified locations.[1]
- 38.2% of verified U.S. TMS clinic locations listed TRICARE in September 2026, equal to 679 locations; the denominator is 1,779 verified locations.[1]
07 Statistics
Delivery & Operations
This section reports supply-side coverage, including 1,779 verified TMS clinic locations operating across the United States as of September 29, 2026.
Delivery capacity and installed base in the tms therapy industry
- 1,779 verified TMS clinic locations operated across the United States as of September 29, 2026; the directory count is a floor because unverified locations were excluded.[1]
- 386 clinicians had a published Medicare CPT 90868 billing record for TMS in 2024, distributed across 254 U.S. cities.[1]
- 289 U.S. mental-health facilities reported offering transcranial magnetic stimulation in the 2024 N-SUMHSS, equal to 2.1% of surveyed facilities.[2]
08 Statistics
Pricing
This section compares public pricing points, including a median $7,472 self-pay price for a standard course in 2026 and $228 per session.
Fees and price levels in the tms therapy industry
- $300–$500 was the typical price range for one TMS therapy session in the United States in 2024, with patients commonly receiving 20–30 sessions.[3]
- $1,530 was University of Colorado Medicine’s listed fee per TMS treatment-delivery and management session in Aurora, Colorado, in its 2025 fee schedule.[4]
- $7,472 was the median published self-pay price for a standard TMS course in the United States in 2026, across 17 clinic price lists; the study defines TMS as conventional repetitive TMS or Deep TMS.[1]
- $180.94 was the average Original Medicare allowed amount per office-based TMS treatment session in the United States in 2024, covering 331,935 sessions.[1]
09 Statistics
Risk & Compliance
This section documents payer policy constraints, including a five-minute maximum emergency-service response time under Blue Cross Blue Shield of Vermont’s 2025 policy.
Regulation and licensing in the tms therapy industry
- Annual review was required for emergency-service relationships and mock drills under Blue Cross Blue Shield of Vermont’s 2025 TMS policy.[5]
- Five minutes was the maximum emergency-service response time specified for facilities administering covered TMS under Blue Cross Blue Shield of Vermont’s 2025 policy.[5]
- 18 years was the minimum patient age specified for covered TMS therapy under Blue Cross Blue Shield of Vermont’s 2025 policy.[5]
Key questions about the tms therapy industry
What is the 2026 market size for transcranial magnetic stimulation system revenue?
How fast does the TMS system market grow between 2026 and 2033?
Which companies lead the tms therapy industry?
What technology shift is affecting adoption of TMS protocols?
How fragmented is the TMS treatment-system authorization landscape in the United States?
What does Medicare reimbursement look like for office-based TMS sessions?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 20). Tms Therapy Industry Statistics. Gitnux. https://gitnux.org/tms-therapy-industry-statistics
Samuel Norberg. "Tms Therapy Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/tms-therapy-industry-statistics.
Samuel Norberg. 2026. "Tms Therapy Industry Statistics." Gitnux. https://gitnux.org/tms-therapy-industry-statistics.
Sources & references
22 sources cited across this report
- tmsinstitute.com
samhsa.gov
carecredit.com
- cumedicine.us
- bluecrossvt.org
grandviewresearch.com
magventure.com
nimh.nih.gov
sec.gov
investors.brainsway.com
fda.gov
cms.gov
med.uth.edu
accessdata.fda.gov
nexstim.com
neurocaregroup.com
- rogue-research.com
- magnusmedical.com
soterixmedical.com
- deymed.pt
magstim.com
- ir.neuronetics.com
